Prostate Cancer
Conditions
Keywords
abiraterone acetate
Brief summary
Neoadjuvant treatment before radical prostatectomy has been proven to provide benefits on peri-operation results, especially on reduction of tumor volume and minimization of biochemical recurrence. This study will evaluate the efficacy and safety of abiraterone acetate Plus androgen deprivation therapy（ADT）in high-risk localized prostate cancer with intraductal carcinoma of the prostate（IDC-P）.
Detailed description
IDC-P is an adverse pathological entity of prostate cancer, characterized by the growth of malignant cells in pre-existing prostatic ducts and acini, and is present in high-grade disease and associated with poor prognosis. Previous studies have shown that IDC-P was significantly associated with an adverse clinical course in patients who received radical prostatectomy or radiotherapy, and the presence of IDC-P on the biopsy specimen was associated with a poor prognosis in terms of overall survival (OS) and a poor docetaxel response in patients with distant metastasis at the initial diagnosis. Our previous researches as well as other published data indicated that abiraterone had a better therapeutic efficacy than docetaxel as the first-line therapy in metastatic castration resistance prostate cancer（mCRPC）with IDC-P. Therefore we intended to perform this single-arm phase II clinical trial to evaluate the initial efficacy and safety of abiraterone acetate Plus ADT as neoadjuvant therapy for high-risk localized prostate cancer with IDC-P. The primary endpoint is the pathologic complete response (pCR).
Interventions
DRUGAbiraterone acetate
1000 mg orally daily for 24 weeks before radical prostatectomy
DRUGPrednisolone
5 mg oral low dose prednisone, once daily
DRUGGoserelin
10.8 mg goserelin hypodermic once per 12 weeks
Sponsors
West China Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Histologically or cytologically diagnosis of prostate cancer with positive IDC-P status * High-risk localized prostate cancer, defined by either: Tumor stage ≥T3a by digital rectal examination, or Primary tumor Gleason score ≥ 8, or PSA \> 20 ng/mL * No evidence of metastases * The ECOG score of the patient is ≤2 * Expected survival over 5 years * Patients must participate voluntarily and sign an informed consent form (ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must be willing to obey the prohibitions and restrictions specified in the research protocol * Agree to collect the tumor tissue and blood samples needed for the research and apply them to related study * Adequate hematologic, renal and hepatic function: * Absolute neutrophil count \[ANC\] ≥1.5 x 10\^9/L * Platelet count \[PLT\] ≥100 x 10\^9/L * Hemoglobin \[HGB\] ≥9 g/dL * Serum Total bilirubin \[TBIL\] ≤1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \< 2.5 x ULN * Serum albumin \[ALB\] ≥2.8 g/dL * Serum Creatinine ≤ 1.5 x ULN * Creatinine Clearance ≥ 40 mL/min
Exclusion criteria
* Prior androgen deprivation therapy (medical or surgical), radiation therapy or chemotherapy for prostate cancer * Evidence of metastatic disease (M1) on imaging studies * Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of the prostate * Major surgery or severe trauma within 30 days before enrollment * Patients with severe or uncontrolled concurrent，including but not limited to： * Severe or uncontrolled concurrent infections * Human immunodeficiency virus \[HIV\] infection positive * Suffer from acute or chronic active hepatitis B (HBsAg positive and HBV DNA\>1x10\^3/mL) Or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA\>15 IU/mL) * Active tuberculosis, etc * Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III or IV heart failure，or clinically significant ventricular arrhythmias * Uncontrolled hypertension（Systolic blood pressure≥160mmHg or Diastolic blood pressure≥100mmHg） * Severe or unstable angina, myocardial infarction，arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks) Occurred within 6 months before enrollment * Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study * Any condition that in the opinion of the investigator, would preclude participation in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic Complete Response Rate（pCR） | 6 months | The proportion of subjects with no morphologically recognizable cancer cell in tumor specimens after radical prostatectomy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Subjects With Minimal Residual Disease | 6 months | The proportion of subjects that have residual tumors with maximum diameter of 5 mm or less after radical prostatectomy. |
| Rate of positive surgical margin (PSM) | 6 months | The rate of positive surgical margins in the prostatectomy specimen after neoadjuvant therapy. |
| Rate of Nodal Metastases After 6 Months of Treatment | 6 months | The rate of the presence of tumor cells within surgically excised lymph nodes will be assessed after 6 months of neoadjuvant treatment. |
| Rate of Pathologic T3 Disease After 6 Months of Treatment | 6 months | The rate of the presence of T3 disease (e.g. extraprostatic tumor not invading adjacent structures) will be determine from the prostatectomy specimen after 6 months of neoadjuvant treatment. |
| Biochemical Progression-free Survival (bPFS) | 2 years | Biochemical progression will be defined per the American Urological Association guidelines (i.e. confirmed prostate-specific antigen post-radical prostatectomy \>= 0.2 ng/mL) or death. Will be estimated using Kaplan-Meier methods and 95% CI will be estimated using Greenwood's formula. |
| PSA decline rate | 6 months | The rate of PSA decline to baseline PSA after 6 months of neoadjuvant therapy. |
| Radiographic progression-free survival (rPFS) | 2 years | Time from surgery to radiographic progression or death |
| Overall survival | 5 years | Time from surgery to death due to any cause |
| Incidence and severity of adverse events | 6 months | Safety as assessed by the incidence and severity of adverse events and serious adverse events graded according to the National Cancer Institute - Common Terminology Criteria for adverse events (CTCAE) version 4.0. |
| Quality of life (QOL) as assessed by FACT-P | Up to 24 months after surgery | The QOL will be measured using the functional assessment of cancer therapy-prostate（FACT-P）. The questionnaires will be administered at baseline, prior to RP and every 3 months for 2 years post RP. |
| Quality of life as assessed by EQ-5D | Up to 24 months after surgery | The QOL will be measured using the EuroQol five dimensions questionnaire（EQ-5D）. The questionnaires will be administered at baseline, prior to RP and every 3 months for 2 years post RP. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Rate of Magnetic Resonance Imaging Downstaging after Neoadjuvant Therapy | 6 months | The rate of MRI imaging downstaging after neoadjuvant therapy |
| Exploratory analysis to correlate tissue expression of PSA, CYP17, Ki67, and AR with pathologic response | 6 months | To correlate the expression of PSA, CYP17, Ki67, and AR by immunohistochemistry with pCR/npCR in the prostatectomy specimen. |
Countries
China
Contacts
Primary ContactHao Zeng, Professor
Outcome results
None listed